proven effective in several biological assays. Final

proof of concept is conducted in animal infection

models.

Thanks to Omnia's technology and design expertise,

pre-clinical timelines and costs are reduced,

and candidate compounds are substantially derisked

in the pre-clinical phase.

Lead compounds are partnered for co-development

with pharma industry at pre-clinical proof-of-concept (validation in standard animal models of infection).